Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
MicroRNA-223 is a crucial mediator of PPARγ-regulated alternative macrophage activation
Wei Ying, … , Stephen Safe, Beiyan Zhou
Wei Ying, … , Stephen Safe, Beiyan Zhou
Published October 5, 2015
Citation Information: J Clin Invest. 2015;125(11):4149-4159. https://doi.org/10.1172/JCI81656.
View: Text | PDF
Research Article Immunology Article has an altmetric score of 2

MicroRNA-223 is a crucial mediator of PPARγ-regulated alternative macrophage activation

  • Text
  • PDF
Abstract

Polarized activation of adipose tissue macrophages (ATMs) is crucial for maintaining adipose tissue function and mediating obesity-associated cardiovascular risk and metabolic abnormalities; however, the regulatory network of this key process is not well defined. Here, we identified a PPARγ/microRNA-223 (miR-223) regulatory axis that controls macrophage polarization by targeting distinct downstream genes to shift the cellular response to various stimuli. In BM-derived macrophages, PPARγ directly enhanced miR-223 expression upon exposure to Th2 stimuli. ChIP analysis, followed by enhancer reporter assays, revealed that this effect was mediated by PPARγ binding 3 PPARγ regulatory elements (PPREs) upstream of the pre–miR-223 coding region. Moreover, deletion of miR-223 impaired PPARγ-dependent macrophage alternative activation in cells cultured ex vivo and in mice fed a high-fat diet. We identified Rasa1 and Nfat5 as genuine miR-223 targets that are critical for PPARγ-dependent macrophage alternative activation, whereas the proinflammatory regulator Pknox1, which we reported previously, mediated miR-223–regulated macrophage classical activation. In summary, this study provides evidence to support the crucial role of a PPARγ/miR-223 regulatory axis in controlling macrophage polarization via distinct downstream target genes.

Authors

Wei Ying, Alexander Tseng, Richard Cheng-An Chang, Andrew Morin, Tyler Brehm, Karen Triff, Vijayalekshmi Nair, Guoqing Zhuang, Hui Song, Srikanth Kanameni, Haiqing Wang, Michael C. Golding, Fuller W. Bazer, Robert S. Chapkin, Stephen Safe, Beiyan Zhou

×

Figure 3

miR-223 deficiency impairs PPARγ-mediated improvement of adipose tissue function under the stress of obesity.

Options: View larger image (or click on image) Download as PowerPoint
miR-223 deficiency impairs PPARγ-mediated improvement of adipose tissue ...
(A and B) Glucose tolerance test and insulin tolerance test (n = 9–10). (C and D) Glucose and insulin plasma concentrations for WT and Mir223-KO mice fed an HFD without (Control) or with pioglitazone (Pio) supplementation or fasted for 16 hours (n = 6–10). (E) Expression of key regulators of lipogenesis, lipolysis, and mitochondrial function in VAT of HFD-fed mice with pioglitazone treatment (Pio) or without (Control) (n = 3). Acc, acetyl-CoA carboxylase; Fas, fatty acid synthetase; Hsl, hormone-sensitive lipase; Scd1, stearoyl-CoA desaturase-1. Data are presented as the mean ± SEM. ‡P < 0.05, HFD–miR-223KO versus HFD–miR-223KO–pio; *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001, HFD-WT versus HFD-WT-pio by 2-way ANOVA (A and B), 1-way ANOVA with Bonferroni’s post test (C and D), and Student’s t test (E).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 6 X users
109 readers on Mendeley
1 readers on CiteULike
See more details